The AI pilot trap: Why promising tools fail to scale
A test of technology can succeed within a small setting. Implementing AI in wider production requires authority, visibility and ownership.
Artificial intelligence in healthcare does not fail because the pilot projects did not demonstrate value. They fail because of the inability to move from a pilot to a governed, supported and trusted operating capability.
Most health systems can point to AI pilots that worked, such as an ambient documentation pilot that reduced charting burden, or a revenue cycle tool that improved denial prioritization, or a scheduling model that predicted no-shows, or an early-warning model that surfaced patient risk.
While those represent real wins and they matter, they often remain isolated. The pilot can be implemented in one department, can be heavily reliant on one vendor integration, one department as clinical champion, one model’s data feed, and one favorable budget cycle.
Then, the organization tries to scale it and discovers that model ownership is not defined, no one can explain whether the input data sources are static or dynamic, clinician trust past the pilot model is not there, and governance is reviewing the tool after the operational decisions have been made.
This creates a pilot trap, and many view it as a technology problem. However, this is an operating model problem.
The challenge in healthcare
Hospitals are accustomed to governing high-risk systems – medical devices, clinical workflows, medications, infection control, patient privacy and many more. AI touches all of them.
A clinical model may depend on EHR data, trigger patient safety alerts, influence nurse or physician workflows, create billing or documentation outputs, and rely on a vendor’s architecture that security and compliance teams must understand.
Treating an AI model implementation as a standalone innovation activity misses how hospitals operate.
Anticipating operational questions
A useful governance model must answer operational questions before production, not after a problem surfaces. These can include the following issues.
These questions are operational. They are not intended to slow down innovation but rather to provide the conditions that determine whether AI can safely move from a pilot proof of concept to enterprise infrastructure.
Can a committee mitigate risk?
Many health systems have responded to AI risk by creating an AI committee. While that’s a useful starting point, that, by itself, is insufficient.
Standalone committees may lack authority over clinical operations, capital planning, EHR change management, vendor procurement, quality and safety reviews, security reviews, and broader risk oversight. A committee can review the AI tool, but it cannot govern the decisions that make AI operational.
A more practical approach is routing. AI governance needs to be integrated into the current decision-making bodies that are already governing hospital operations. For example, medication-related AI may require pharmacy, therapeutics and medication safety review. A deterioration model may belong with quality, patient safety, nursing and clinical operations. Revenue cycle automation belongs with revenue cycle leadership, finance, compliance and information technology. Vendor AI may belong in procurement, legal, privacy, cybersecurity and enterprise architecture review.
Sensible routing for AI
Just as AI models will need multi-agent systems for each function, there needs to be routing of the AI governance across multiple decision-making bodies.
The routing model does not eliminate the need for a central AI governance function; rather, it gives that function a realistic way to operate inside the hospital.
In tackling innovation implementation, the lesson from the old adage, “Don’t let perfect be the enemy of good,” is helpful in the early stages of the AI journey. An AI platform does not need to be perfect before it can govern AI. The need here is for a staged operating model that matures over time.
This practical roadmap encompasses four layers. These include governance and accountability; stable data pipelines; shared infrastructure and model architecture; and clinical adoption and dynamic architecture.
The sequence of the roadmap matters. Governance without data visibility becomes performative. Data pipelines without shared infrastructure become overly expensive to maintain. Infrastructure without adoption becomes unused technology and sunk cost investment. Adoption without dynamic governance becomes trust without surveillance.
The goal is not to slow innovation; it is to make innovation repeatable.
A pilot can succeed with energy from its sponsors and local work arounds when problems crop up. A production AI technology stack requires authority, visibility and ownership.
The health systems that will scale AI will not be the ones that have the most successful pilots. It will be the ones that turn their pilots into governed operating capabilities.
Endrit Meta, MS, is senior director of technology and data at WellLink. In his role, Meta provides leadership within WellLink’s data and technology hub.